FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to human interleukin-2 (IL-2) muteins, and can be used in medicine in treating cancer. Disclosed is modified IL-2, which contains only two amino acid substitutions in positions P65 and S125 SEQ ID NO: 3; or only three amino acid substitutions in positions of amino acid residues L19, P65 and S125 of SEQ ID NO: 3, or only four amino acid substitutions in positions of amino acid residues L19, P65, S125 and Q126 SEQ ID NO: 3.
EFFECT: invention provides obtaining mutant IL-2, which demonstrates reduced binding to IL-2Rα (interleukin-2 alpha receptor) with reduced activity on Treg (regulatory T-cell) compared to the polypeptide presented in SEQ ID NO: 3, but retaining the ability to bind to IL 2Rβγ complex (interleukin-2 beta gamma receptor) and activate it.
14 cl, 34 dwg, 15 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSED PROTEINS WITH ALBUMIN-BINDING DOMAINS | 2018 |
|
RU2786444C2 |
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
| LIGAND-BINDING MOLECULE WITH REGULATED LIGAND-BINDING ACTIVITY | 2017 |
|
RU2803067C2 |
| ANTIBODIES TO IL-6 AND THEIR FUSIONS AND CONJUGATES | 2019 |
|
RU2810777C2 |
| POLYPEPTIDE COMPRISING ANTIGEN-BINDING DOMAIN AND TRANSPORT SEGMENT | 2018 |
|
RU2815452C2 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2012 |
|
RU2698655C2 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2019 |
|
RU2728861C1 |
| POLYPEPTIDE COMPRISING ANTIGEN-BINDING DOMAIN AND TRANSPORT SEGMENT | 2017 |
|
RU2827545C2 |
| MULTIFUNCTIONAL FUSION PROTEINS AND THEIR USE | 2020 |
|
RU2815388C2 |
| ANTIBODIES DIRECTED AGAINST INTERLEUKIN-33 (IL-33) | 2015 |
|
RU2829846C2 |
